Stock 301089 TUOXIN PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tuoxin Pharmaceutical Group Co.,Ltd.

Equities

301089

CNE100004YC3

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-05-19 EDT 		5-day change 1st Jan Change
39.14 CNY +0.49% Intraday chart for Tuoxin Pharmaceutical Group Co.,Ltd. -8.68% -27.53%
04-22 Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-22 Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 10,130 9,072 6,835
Enterprise Value (EV) 1 9,695 8,565 6,495
P/E ratio 122 x 31.7 x 28 x
Yield 0.12% 0.56% 0.46%
Capitalization / Revenue 20.2 x 11.6 x 8.18 x
EV / Revenue 19.3 x 10.9 x 7.77 x
EV / EBITDA 84.4 x 24.6 x 18.8 x
EV / FCF -69.6 x 75.1 x -45.8 x
FCF Yield -1.44% 1.33% -2.18%
Price to Book 9.23 x 6.59 x 4.26 x
Nbr of stocks (in thousands) 126,000 126,000 126,545
Reference price 2 80.40 72.00 54.01
Announcement Date 4/21/22 4/25/23 4/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 391 386 527.9 502.5 784.7 835.5
EBITDA 1 99.51 95.94 158.3 114.8 348.3 346.3
EBIT 1 83.45 79.54 140.9 83.92 307.8 299.7
Operating Margin 21.34% 20.61% 26.7% 16.7% 39.22% 35.88%
Earnings before Tax (EBT) 1 77.77 70.37 135.4 78.04 325.3 316.5
Net income 1 63.22 61.25 112.8 65.71 286.5 243.1
Net margin 16.17% 15.87% 21.37% 13.08% 36.51% 29.09%
EPS 2 0.6700 0.6500 1.190 0.6600 2.270 1.930
Free Cash Flow 1 73.93 -7.509 58.57 -139.2 114.1 -141.8
FCF margin 18.91% -1.95% 11.09% -27.7% 14.54% -16.97%
FCF Conversion (EBITDA) 74.3% - 36.99% - 32.76% -
FCF Conversion (Net income) 116.95% - 51.92% - 39.82% -
Dividend per Share - - - 0.1000 0.4000 0.2500
Announcement Date 1/29/21 1/29/21 9/28/21 4/21/22 4/25/23 4/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 30.9 72.6 17.4 - - -
Net Cash position 1 - - - 435 507 339
Leverage (Debt/EBITDA) 0.3103 x 0.7564 x 0.1096 x - - -
Free Cash Flow 1 73.9 -7.51 58.6 -139 114 -142
ROE (net income / shareholders' equity) 22.2% 17.5% 25.8% 8.27% 23.2% 16.3%
ROA (Net income/ Total Assets) 8.3% 6.82% 10.4% 4.48% 11.9% 10.2%
Assets 1 762.1 898.1 1,080 1,466 2,411 2,389
Book Value Per Share 2 3.340 4.050 5.190 8.710 10.90 12.70
Cash Flow per Share 2 1.860 1.100 1.670 2.260 2.440 1.170
Capex 1 61.5 76.2 74.1 113 148 185
Capex / Sales 15.74% 19.74% 14.04% 22.43% 18.9% 22.17%
Announcement Date 1/29/21 1/29/21 9/28/21 4/21/22 4/25/23 4/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
TUOXIN PHARMACEUTICAL GROUP CO.,LTD. Stock Tuoxin Pharmaceutical Group Co.,Ltd.
-27.53% 682M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.63% 44.12B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.99% 22.71B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.22% 15.15B
CIPLA LIMITED Stock Cipla Limited
+12.66% 13.61B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+60.18% 13.34B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.35% 6.84B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+15.65% 5.63B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301089 Stock
  4. Financials Tuoxin Pharmaceutical Group Co.,Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW